Fungi Perfecti Publishes New Study on Agarikon Mycelium and Immune Responses

OLYMPIA, Wash., Sept. 10, 2026 /CourierPR/ -- Fungi Perfecti, LLC, a company known for its research into fungi and functional mushrooms, has published new findings in the peer-reviewed journal Frontiers in Immunology. The study, titled "Adaptive Resilience: Agarikon Mycelium Modulates Immune Responses and Provides Oxidative Stress Buffering in Human Immune Cells," explores the interactions between Agarikon mycelium and human immune cells under both basal and LPS-stimulated conditions.

According to the research, Agarikon mycelium, traditionally used in various wellness practices, demonstrated a context-dependent response profile. In basal conditions, the fungus influenced gene expression patterns related to innate immune signaling pathways, including IL-1 and NF-κB pathways. The study also observed changes in select immune mediators such as IL-1RA and decreases in certain toll-like receptor transcripts.

Under LPS-stimulated conditions, which simulate immune stress, the immune response profile shifted in a manner consistent with balanced immune signaling. Increases in select immune effectors, including TLR5, were noted, along with changes associated with cytokine signaling.

Chase Beathard, PhD, Director of Research and Development at Fungi Perfecti, explained, "During our study evaluations, we observed changes in immune cell signaling under healthy, basal conditions that may be consistent with immune preparedness. In the laboratory stress-challenge model, the changes we observed displayed a context-dependent pattern consistent with balanced immune signaling."

The research builds on Fungi Perfecti's commitment to exploring the biological activity of Agarikon, a rare, slow-growing fungus typically found in old-growth forest habitats. Fungi Perfecti maintains the world's largest Agarikon strain library, collecting cultures from over 120 specimens after several decades of research. The company's efforts aim to support human and planetary immunity, considering it key elements for protecting the collective future.

Paul Stamets, Founder, Member, and Owner at Fungi Perfecti, commented, "In these rapidly changing times, supporting human and planetary immunity should be considered key elements for protecting our collective future. Agarikon is a stellar example of the common interests we share from ancient times to the present. Our dedicated research has led to, and is leading to, several publications like this. The continuing story of exploring Agarikon for supporting immunity is compelling."

The findings from this preclinical study suggest a coordinated response profile that supports further investigation. While the results are from a laboratory model and do not necessarily demonstrate effects in humans, they provide a foundation for future clinical validation.